Low-dose growth hormone replacement lowers plasma leptin and fat stores without affecting body mass index in adults with growth hormone deficiency

C. M. Florkowski, G. R. Collier, P. Z. Zimmet, J. H. Livesey, E. A. Espiner, R. A. Donald

Research output: Contribution to journalArticle

91 Citations (Scopus)

Abstract

Objective: The ob gene product, leptin, is considered to be a marker of adipose tissue mass and a possible homeostatic regulator of body mass. Our objective was to examine the effect of GH replacement on adipose tissue stores and leptin in adult hypopituitarism. Subjects: Twenty adults, mean age 47 years (range 20-69) with proven GH deficiency were randomly allocated to either GH (up to 0.25 U/kg/week in daily doses) or placebo for 3 months before cross-over to the opposite treatment. Measurements: Body composition was measured by dual-energy X-ray absorptiometry (DEXA) in the whole body, trunk and limbs. Plasma leptin was measured by radioimmunoassay at baseline and +2, +4, +8 and +12 weeks in each treatment arm. Results: Total body tissue fat (mean ± SE) was 30.1 ± 2.2% after GH compared with 31.9 ± 2.2% after placebo, P < 0.001 (ANOVA). There were no significant changes in BMI (kg/m2), 29.1 ± 1.3 after placebo vs 28.8 ± 1.2 after GH; or waist to hip ratio (WHR), 0.91 ± 0.01 after both placebo and GH. Baseline plasma leptin showed a significant correlation with baseline BMI, r = 0.67, P < 0.005 and baseline percentage total body fat, R = 0.89, P < 0.001. Plasma leptin (adjusted by using baseline percentage total body fat as a covariate) showed a significant linear decrease with time on GH compared with placebo (P = 0.03, ANOVA). Conclusions: Plasma leptin and total body fat fall promptly in response to low-dose replacement of GH in GH-deficient subjects. Hormone-induced changes in leptin can occur in humans in the absence of change in body mass index.

LanguageEnglish
Pages769-773
Number of pages5
JournalClinical Endocrinology
Volume45
Issue number6
DOIs
Publication statusPublished - 1996
Externally publishedYes

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Florkowski, C. M. ; Collier, G. R. ; Zimmet, P. Z. ; Livesey, J. H. ; Espiner, E. A. ; Donald, R. A. / Low-dose growth hormone replacement lowers plasma leptin and fat stores without affecting body mass index in adults with growth hormone deficiency. In: Clinical Endocrinology. 1996 ; Vol. 45, No. 6. pp. 769-773.
@article{eab5903d30da4d0e966769b2415a0ae9,
title = "Low-dose growth hormone replacement lowers plasma leptin and fat stores without affecting body mass index in adults with growth hormone deficiency",
abstract = "Objective: The ob gene product, leptin, is considered to be a marker of adipose tissue mass and a possible homeostatic regulator of body mass. Our objective was to examine the effect of GH replacement on adipose tissue stores and leptin in adult hypopituitarism. Subjects: Twenty adults, mean age 47 years (range 20-69) with proven GH deficiency were randomly allocated to either GH (up to 0.25 U/kg/week in daily doses) or placebo for 3 months before cross-over to the opposite treatment. Measurements: Body composition was measured by dual-energy X-ray absorptiometry (DEXA) in the whole body, trunk and limbs. Plasma leptin was measured by radioimmunoassay at baseline and +2, +4, +8 and +12 weeks in each treatment arm. Results: Total body tissue fat (mean ± SE) was 30.1 ± 2.2{\%} after GH compared with 31.9 ± 2.2{\%} after placebo, P < 0.001 (ANOVA). There were no significant changes in BMI (kg/m2), 29.1 ± 1.3 after placebo vs 28.8 ± 1.2 after GH; or waist to hip ratio (WHR), 0.91 ± 0.01 after both placebo and GH. Baseline plasma leptin showed a significant correlation with baseline BMI, r = 0.67, P < 0.005 and baseline percentage total body fat, R = 0.89, P < 0.001. Plasma leptin (adjusted by using baseline percentage total body fat as a covariate) showed a significant linear decrease with time on GH compared with placebo (P = 0.03, ANOVA). Conclusions: Plasma leptin and total body fat fall promptly in response to low-dose replacement of GH in GH-deficient subjects. Hormone-induced changes in leptin can occur in humans in the absence of change in body mass index.",
author = "Florkowski, {C. M.} and Collier, {G. R.} and Zimmet, {P. Z.} and Livesey, {J. H.} and Espiner, {E. A.} and Donald, {R. A.}",
year = "1996",
doi = "10.1046/j.1365-2265.1996.830895.x",
language = "English",
volume = "45",
pages = "769--773",
journal = "Clinical Endocrinology",
issn = "0300-0664",
publisher = "Wiley-Blackwell",
number = "6",

}

Low-dose growth hormone replacement lowers plasma leptin and fat stores without affecting body mass index in adults with growth hormone deficiency. / Florkowski, C. M.; Collier, G. R.; Zimmet, P. Z.; Livesey, J. H.; Espiner, E. A.; Donald, R. A.

In: Clinical Endocrinology, Vol. 45, No. 6, 1996, p. 769-773.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Low-dose growth hormone replacement lowers plasma leptin and fat stores without affecting body mass index in adults with growth hormone deficiency

AU - Florkowski, C. M.

AU - Collier, G. R.

AU - Zimmet, P. Z.

AU - Livesey, J. H.

AU - Espiner, E. A.

AU - Donald, R. A.

PY - 1996

Y1 - 1996

N2 - Objective: The ob gene product, leptin, is considered to be a marker of adipose tissue mass and a possible homeostatic regulator of body mass. Our objective was to examine the effect of GH replacement on adipose tissue stores and leptin in adult hypopituitarism. Subjects: Twenty adults, mean age 47 years (range 20-69) with proven GH deficiency were randomly allocated to either GH (up to 0.25 U/kg/week in daily doses) or placebo for 3 months before cross-over to the opposite treatment. Measurements: Body composition was measured by dual-energy X-ray absorptiometry (DEXA) in the whole body, trunk and limbs. Plasma leptin was measured by radioimmunoassay at baseline and +2, +4, +8 and +12 weeks in each treatment arm. Results: Total body tissue fat (mean ± SE) was 30.1 ± 2.2% after GH compared with 31.9 ± 2.2% after placebo, P < 0.001 (ANOVA). There were no significant changes in BMI (kg/m2), 29.1 ± 1.3 after placebo vs 28.8 ± 1.2 after GH; or waist to hip ratio (WHR), 0.91 ± 0.01 after both placebo and GH. Baseline plasma leptin showed a significant correlation with baseline BMI, r = 0.67, P < 0.005 and baseline percentage total body fat, R = 0.89, P < 0.001. Plasma leptin (adjusted by using baseline percentage total body fat as a covariate) showed a significant linear decrease with time on GH compared with placebo (P = 0.03, ANOVA). Conclusions: Plasma leptin and total body fat fall promptly in response to low-dose replacement of GH in GH-deficient subjects. Hormone-induced changes in leptin can occur in humans in the absence of change in body mass index.

AB - Objective: The ob gene product, leptin, is considered to be a marker of adipose tissue mass and a possible homeostatic regulator of body mass. Our objective was to examine the effect of GH replacement on adipose tissue stores and leptin in adult hypopituitarism. Subjects: Twenty adults, mean age 47 years (range 20-69) with proven GH deficiency were randomly allocated to either GH (up to 0.25 U/kg/week in daily doses) or placebo for 3 months before cross-over to the opposite treatment. Measurements: Body composition was measured by dual-energy X-ray absorptiometry (DEXA) in the whole body, trunk and limbs. Plasma leptin was measured by radioimmunoassay at baseline and +2, +4, +8 and +12 weeks in each treatment arm. Results: Total body tissue fat (mean ± SE) was 30.1 ± 2.2% after GH compared with 31.9 ± 2.2% after placebo, P < 0.001 (ANOVA). There were no significant changes in BMI (kg/m2), 29.1 ± 1.3 after placebo vs 28.8 ± 1.2 after GH; or waist to hip ratio (WHR), 0.91 ± 0.01 after both placebo and GH. Baseline plasma leptin showed a significant correlation with baseline BMI, r = 0.67, P < 0.005 and baseline percentage total body fat, R = 0.89, P < 0.001. Plasma leptin (adjusted by using baseline percentage total body fat as a covariate) showed a significant linear decrease with time on GH compared with placebo (P = 0.03, ANOVA). Conclusions: Plasma leptin and total body fat fall promptly in response to low-dose replacement of GH in GH-deficient subjects. Hormone-induced changes in leptin can occur in humans in the absence of change in body mass index.

UR - http://www.scopus.com/inward/record.url?scp=0030462283&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2265.1996.830895.x

DO - 10.1046/j.1365-2265.1996.830895.x

M3 - Article

VL - 45

SP - 769

EP - 773

JO - Clinical Endocrinology

T2 - Clinical Endocrinology

JF - Clinical Endocrinology

SN - 0300-0664

IS - 6

ER -